What's the Outlook for Moderna Stock?

Zhiyuan Sun, The Motley Fool
·5-min read
What's the Outlook for Moderna Stock?
What's the Outlook for Moderna Stock?

On Nov. 16, large-cap biotech Moderna (NASDAQ: MRNA) reported that its experimental messenger RNA (mRNA) vaccine (mRNA-1273) is nearly 95% effective at immunizing patients against COVID-19. This was the third time a coronavirus vaccine candidate demonstrated efficacy in a large-scale placebo-controlled phase 3 study, following Pfizer (NYSE: PFE) and BioNTech's (NASDAQ: BNTX) BNT162b2 and the Russian government's Sputnik V. Moderna's mRNA-1273 is set to be released in a hypercompetitve coronavirus vaccine market.